Our expert, Maria Castellà, participated this week in the ATMP Catalonia Series event, organized by Vall d’Hebron Institut de Recerca (VHIR) in collaboration with Biocat. The session, “ATMPs: From Preclinical Discovery to First-in-Human Trials”, gathered leading voices from academia, industry, and clinical research to discuss the scientific, regulatory, and clinical challenges of advanced therapy medicinal products (ATMPs).
Maria Castellà’s key takeaway from the discussion:
“Enhancing the currently limited funding options and bridging the knowledge gap regarding regulatory expectations and procedures for drug developers will address the existing shortcomings in ATMP development from academic centers. This approach will facilitate a greater number of ATMP products reaching patients.”
The discussion highlighted the importance of early regulatory planning, collaboration between stakeholders, and ensuring the translation of innovative therapies from the lab to patients. At Asphalion, we are proud to contribute our expertise to support the development of advanced therapies and help bring them safely to patients.
Need support with your ATMPs or other regulatory requirements?
Contact us at: [email protected]
